Eventually, we divided ccRCC samples into PHLDA2-high (PHLDA2-H) and PHLDA2-low (PHLDA2-L) subgroups based on stratification by median expression of PHLDA2, and compared the mutational landscape between the two subgroups. This evidence concerns the gene PHLDA2 and nonpapillary renal cell carcinoma.